Background Metabolic syndrome (MetS) is a cluster of metabolic risk factors which increases the chances for future cardiovascular diseases, as well as diabetes. The underlying causes of MetS include overweight and obesity, physical inactivity and genetic factors. Our intension here was to focus in this study on the importance of the chronobiology, represented by melatonin (MT) and cryptochrome 2 (CRY2), in developing MetS and type 2 diabetes mellitus (T2DM). Thus, we aimed to compare MT and CRY2 plasma levels and correlate both biomarkers with adiposity, atherogenicity and hematological indices in MetS and T2DM cohorts. Methods In a cross-sectional study, 28 normoglycemic lean subjects (controls), 29 normoglycemic MetS subjects and 30 MetS (pre-diabetic/diabetic) were recruited. Results MT (pg/mL) was elevated significantly in MetS arm p-value < 0.05, whereas CRY2 levels (ng/mL) were markedly higher in both MetS groups (non-diabetic and pre-diabetic/diabetic) (all with p-value < 0.001). A reciprocal MT-CRY2 relationship was observed in the MetS (non-diabetic) group (p-value = 0.003). Of note in the total study population, both MT and CRY2 proportionally correlated with each of the following: atherogenicity index of plasma (AIP), waist circumference (WC) and systolic blood pressure (SBP) (all with p-value < 0.05) for MT and CRY2, respectively). Whereas MT correlated inversely with high-density lipoprotein-cholesterol (HDL-C) (p-value < 0.05). Additionally, CRY2 correlated directly with each of the following: diastolic blood pressure (DBP), total cholesterol (TC), low-density lipoprotein (LDL-C), hip circumference (HC), body adiposity index (BAI), weight-to-height (WHtR) ratio, mean platelet volume (MPV) and platelet/lymphocyte ratio (PLR) (p-value < 0.05). Conclusion These findings substantiate that both metabolic risk biomarkers can be prognostic tools and pharmacotherapeutic targets to slowdown the accelerated nature of T2DM.
Inhalt
- Original Articles
-
Erfordert eine Authentifizierung Nicht lizenziertMelatonin and cryptochrome 2 in metabolic syndrome patients with or without diabetes: a cross-sectional studyLizenziert29. Mai 2018
-
Erfordert eine Authentifizierung Nicht lizenziertChanges to trimethylamine-N-oxide and its precursors in nascent metabolic syndromeLizenziert18. April 2018
-
Erfordert eine Authentifizierung Nicht lizenziertIs FGF23 effective on insulin resistance in individuals with metabolic syndrome?Lizenziert12. Juli 2018
- Review Article
-
Erfordert eine Authentifizierung Nicht lizenziertCirculating low density lipoprotein (LDL)Lizenziert31. Juli 2018
- Case Report
-
Erfordert eine Authentifizierung Nicht lizenziertCongenital complete heart block in pregnancyLizenziert25. August 2018